CJC-1295 + Ipamorelin 5 mg / 5 mg, glass vial, crimp seal, flip-top cap, California Standard Peptides label

Blends

CJC-1295 + Ipamorelin

A single vial containing CJC-1295 (no DAC) and ipamorelin. One is a GHRH-receptor agonist and the other a ghrelin-receptor agonist; published research examines them individually, not as this combination.

5 mg / 5 mgCS-CJIP-5-5$90.00
10 mg / 10 mgCS-CJIP-10-10$150.00
Choose a size and add to cart →
Container
Glass vial, crimp seal, flip-top cap
Storage
-20 °C, desiccated
In the vial
CJC-1295 (no DAC) + Ipamorelin
Paperwork
Lot certificate (HPLC + mass spec) shown before you pay

Lot certificates

You’ll see American Peptides on the lab’s copy. They’re our supplier.

  • 5 mg / 5 mg, lot CJCIP10-0803: 99.80% purity (RP-HPLC), 5.13 mg / 5.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7607
  • 10 mg / 10 mg, lot CJCIP20-0803: 99.82% purity (RP-HPLC), 10.62 mg / 10.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7631

Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.

What researchers study it for

  • Structural analog of GHRH(1-29)
  • Doping-control detection in seized material
  • Selective growth hormone release
  • Pituitary hormone selectivity in animal models

How it is thought to work

CJC-1295 (no DAC): As a GHRH(1-29) analog, it is expected to act on the GHRH receptor of pituitary somatotrophs, but this is inferred from related compounds rather than measured directly. Ipamorelin: Ipamorelin acts on the ghrelin receptor (GHS-R1a), stimulating growth hormone release from the pituitary.

Where the research stands

Blend of research compounds. Each component is studied separately; as a combined vial it has no dedicated published research. The least-established component is CJC-1295 (no DAC): no published human studies.

Sources

  1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology.
  2. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne).
  3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol.
  4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharm Res.

Read more

For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.

California Standard Peptides

Your cart

0 items · free shipping over $200.00

Your cart is empty.

Buy 2 of a vial and save 10%, 3 and save 15%. Research sets are 15% off, and shipping is free over $200.00.

First order

20% off your first order.

Join the list for first word on new lots, restocks and member pricing. Your code arrives by email and applies by itself at checkout.

One code per email, for your first order. By signing up you agree to get emails from us. Unsubscribe anytime.

For laboratory research use only. 21+.